The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Makers Met with Trump to Argue against Senate Pricing Bill

Drug Makers Met with Trump to Argue against Senate Pricing Bill

July 30, 2019 • By Michael Erman, Carl O'Donnell, Caroline Humer and Roberta Rampton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The main pharmaceutical industry lobbying group said on Thursday it and some drugmakers met with President Donald Trump to voice opposition to a bipartisan U.S. Senate bill that aims to lower prescription drug prices.

You Might Also Like
  • Senate Democrats Introduce Bill to Allow Government to Block Drug Price Rises
  • Trump Urges U.S. Senate Republicans to Keep Trying on Healthcare Bill
  • Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices

The White House, which has said it backs the legislation, has promised to bring down drug prices for U.S. consumers, an important campaign issue for Trump, a Republican, as well as for Democratic rivals vying to oppose him in the November 2020 presidential election.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reuters reported on Wednesday that Trump is considering a sweeping executive order that would cut prices on virtually all branded prescription drugs sold to Medicare and other government programs, according to two industry sources who had discussions with the White House.

Medicare is the U.S. government program that provides health coverage to people aged 65 and older, or who are disabled.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Senate bill moved out of the Senate Finance committee on Thursday morning and to the floor, the next step in the legislative process. White House spokesman Judd Deere tweeted on Thursday that it applauded the move.

PhRMA, the lobbying group, said in a news release on Thursday that the legislation was not the right approach to keep drug prices down and that it imposes harmful price controls in Medicare Part D, the program for self-administered prescription drugs.

It did not disclose which companies accompanied it to the meeting with Trump and was not immediately available for further comment.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Amgen Inc. confirmed that it had attended the meeting but declined further comment.

A source familiar with the situation said Pfizer was also present. A second source said U.S. Department of Health and Human Services Secretary Alex Azar was also there. Politico first reported about the meeting late on Wednesday.

The Senate bill aims to lower drug prices by forcing pharmaceutical companies to pay rebates to Medicare if they raise prices above the rate of inflation.

The proposal also suggests a cap on out-of-pocket costs for drugs covered under Medicare’s Part D and changes to the program’s Part B that covers physician-administered drugs. (Reporting by Michael Erman, Carl O’Donnell and Caroline Humer in New York, Roberta Rampton in Washington D.C. and Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)

Filed Under: Legislation & Advocacy, Pharma Co. News Tagged With: bipartisan U.S. Senate bill, Medicare, Medicare Part D, PhRMA, prescription drug prices

You Might Also Like:
  • Senate Democrats Introduce Bill to Allow Government to Block Drug Price Rises
  • Trump Urges U.S. Senate Republicans to Keep Trying on Healthcare Bill
  • Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices
  • Trump Seeks to Base Medicare Drug Prices on Lower Overseas Rates

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)